Haisco Pharmaceutical's HSK46575 IND accepted for prostate cancer combination therapy

Haisco Pharmaceutical Group Co., Ltd. announced on December 23, 2025, that its subsidiary, Liaoning Haisco Pharmaceutical Co., Ltd., received a notice of acceptance from the National Medical Products Administration for an Investigational New Drug (IND) application for new indications of HSK46575 tablets. This innovative drug is intended for the treatment of prostate cancer, specifically in combination with olaparib tablets or docetaxel and prednisone tablets. The company noted that HSK46575 is currently undergoing Phase I clinical research for prostate cancer, with prior approval received in December 2024.

This IND acceptance underscores Haisco's commitment to advancing its innovative drug pipeline and aligns with its strategic focus on oncology. The company projects a total investment of CNY 96,525.67 for new drug research and development, which includes the HSK46575 project. The successful progression of HSK46575 through clinical trials could significantly enhance Haisco Pharmaceutical's market competitiveness and contribute to future revenue growth in the pharmaceutical sector.